Hemogenyx Pharmaceuticals (HEMO) Stock Price Up 6.1%
Hemogenyx Pharmaceuticals PLC (LON:HEMO) shares rose 6.1% during trading on Thursday . The company traded as high as GBX 2.60 ($0.03) and last traded at GBX 2.60 ($0.03). Approximately 190,000 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 8,010,000 shares. The stock had previously closed at GBX 2.45 ($0.03).
About Hemogenyx Pharmaceuticals (LON:HEMO)
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants.
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.